← Back to Search

Treatment for Achondroplasia

N/A
Recruiting
Research Sponsored by QED Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Summary

This is a long-term, multi-center, observational study in children 2.5 to \<17 years with achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications, assessments of health-related quality of life, body pain, functional abilities, cognitive functions, and treatments of study participants. No study medication will be administered.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Collection of natural history of achondroplasia symptoms in children with achondroplasia
To characterize achondroplasia symptoms in children with achondroplasia

Find a Location

Who is running the clinical trial?

QED Therapeutics, Inc.Lead Sponsor
9 Previous Clinical Trials
878 Total Patients Enrolled
3 Trials studying Achondroplasia
494 Patients Enrolled for Achondroplasia
QED Therapeutics, Inc. VP, Clinical DevelopmentStudy DirectorQED Therapeutics
QED Therapeutics VP, Clinical DevelopmentStudy DirectorQED Therapeutics
2 Previous Clinical Trials
384 Total Patients Enrolled
2 Trials studying Achondroplasia
384 Patients Enrolled for Achondroplasia
~62 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top